Tobacco-based influenza vaccine hailed a promising alternative to egg-based methods

11 March 2016
mitsubishi-tanabe-big

A new tobacco-based seasonal influenza vaccine could potentially rival traditional egg-based versions, an analyst with research and consulting firm GlobalData has said.

The vaccine, which is being developed by Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508), is currently in Phase III development and aims to launch in the USA for the 2018/19 flu season.

It involves the implanting of influenza genetic material into tobacco leaves, a manufacturing process originally developed by Medicago (TSX: MDG), a Canadian biopharmaceutical company which was acquired by Mitsubishi Tanabe Pharma in 2013.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical